-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Good News! Shijiazhuang No.4 Pharmaceutical has developed moxifloxacin hydrochloride ophthalmic solution and levofloxacin sodium chloride injection, while the Group’s Guangxiang Pharmaceutical has had three epalrestat API products consecutively approved.
Category:
TIME：2022-03-19
【SUMMARY】
On March 18, two Class 4 chemical pharmaceutical products developed by Shijiazhuang Sihua Pharmaceutical Co., Ltd.—moxifloxacin hydrochloride ophthalmic solution and levofloxacin sodium chloride injection—were granted Drug Registration Certificates by the National Medical Products Administration and are deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs. In addition, the epalrestat API submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has also been approved by the National Medical Products Administration for use in marketed dosage forms.
The spring breeze brings good news, heralding new developments in pharmaceutical R&D. On March 18, Shijiazhuang Sihua Pharmaceutical Co., Ltd. received Drug Registration Certificates from the National Medical Products Administration for two Class 4 chemical drugs it has developed: moxifloxacin hydrochloride ophthalmic solution and levofloxacin sodium chloride injection. These products are also deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs. In addition, the epalrestat API submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has also been approved by the National Medical Products Administration and may now be used in marketed formulations.
According to reports, moxifloxacin hydrochloride ophthalmic solution is primarily indicated for the treatment of bacterial conjunctivitis caused by susceptible microorganisms and represents Shijiazhuang Sihua Pharmaceutical’s first approved ophthalmic formulation. Levofloxacin is a fluoroquinolone antibiotic mainly used to treat respiratory, urinary, genitourinary, skin and soft-tissue, intestinal, and other infections caused by susceptible bacteria. Epalrestat formulations are primarily indicated for the treatment of diabetic neuropathy. The approval of these three new products will further enhance the Group’s pipeline of formulated products and specialty APIs.
To date, Shijiazhuang Sihua Pharmaceutical has had 20 drug varieties and 28 dosage forms either approved or deemed to have passed the consistency evaluation.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
Business License
